UK-based Theramex has agreed to acquire exclusive licensing and supply rights from TherapeuticsMD to commercialise BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) ...
At the beginning of 2019, Rafarma JSC launched the first anticancer drugs Rozustin® (INN Bendamustin) and Pemelan® (INN Pemetrexed) in its own portfolio. Rosustin® for leukemia treatment has become th...
Novartis signed an agreement with CELLforCURE to produce innovative cancer treatments known as CAR-T therapies (chimeric antigen receptor T-cells) at the bioproduction site based in Les Ulis (Essonne).
Peptonic Medical AB (Sweden) entered a tech transfer agreement with Orion Contract Manufacturing Organisation (CMO) (Finland) to prepare for the commercial manufacture of VagiVital - a product that Peptonic plans to launch.
TxCell and Lonza entered into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.
“Special Investment Contract cannot provide guarantees for the implementation of unfair activities,” said Timofey Nizhegorodtsev, the Head of the Department for Control over Social Sphere and Trade of FAS of Russia.
In the near future, the company will localize the manufacturing of several innovative products in Russia. The transfer of manufacturing to Russia will increase the availability of the drug and contribute to reducing its price.
Telix Pharmaceuticals, a biopharmaceutical company focused on the development of targeted radiopharmaceuticals or “molecularly-targeted radiation”, announced the establishment Telix Pharmaceuticals Japan